| Patient | Edward W. Brooke |
|---|---|
| Date of birth | 1919-10-26 |
| Identifiers | MRN HR-ML014-SYN-TD; SSN (made up) 000-14-5063 |
| Document date | 2003-05-12 |
| Author | Howard Bellamy, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month follow-up on tamoxifen; germline result. [S]
Mr. Brooke returns three months after his last visit, about six and a half months into tamoxifen. He has missed no doses; his pill organizer is empty on the right days. Hot flashes are unchanged, mild, two or three times a week. Asked today about sexual side effects, which were not covered at the last visit, he says his libido has been lower since starting tamoxifen; erections are adequate, and he is not troubled enough to want treatment. He has had no leg swelling or pain, chest pain, breathlessness, or change in vision, and no new lump or swelling on the chest wall or in either armpit. He met the genetic counselor four weeks ago: the multigene panel found no pathogenic variant in BRCA2, BRCA1, PALB2, CHEK2, ATM, or the other genes tested, and he was given a letter to share with his relatives. He takes vitamin D daily and walks most days. [S]
| Element | Detail |
|---|---|
| Tamoxifen | About six and a half months; no missed doses |
| Side effects | Mild hot flashes; lower libido, not bothersome; no clot symptoms |
| Genetics | No pathogenic germline variant; family letter given |
| Recurrence symptoms | None |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fatigue or weight loss |
| Endocrine | Positive | Mild hot flashes |
| Genitourinary | Positive | Lower libido; erections adequate; no urinary symptoms |
| Cardiovascular | Negative | No chest pain or leg swelling or pain |
| Eyes | Negative | No change in vision |
| Psychiatric | Negative | Mood good; PHQ-2 score 1 |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Tamoxifen 20 mg oral tablet, one tablet by mouth once daily (adjuvant endocrine therapy, planned for at least five years) | One tablet once daily | Oral route | 2002-10-28 | active | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2003-02-10 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2003-05-12 | Body height | 183 | cm | S |
| 2003-05-12 | Body weight | 82.2 | kg | S |
| 2003-05-12 | Body mass index (BMI) [Ratio] | 24.5 | kg/m2 | S |
| 2003-05-12 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2003-05-12 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2003-05-12 | Heart rate | 66 | /min | S |
| 2003-05-12 | Respiratory rate | 14 | /min | S |
| 2003-05-12 | Body temperature | 36.6 | Cel | S |
| 2003-05-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2003-05-12 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 36 | ng/mL | 30-100 ng/mL | Normal | S |
| 2003-05-12 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S |
Vital signs recorded on 2003-05-12; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Chest wall | Mastectomy scars healed on both sides; no nodule or skin change |
| Lymph nodes | No axillary, supraclavicular, or cervical nodes |
| Extremities | Arm circumferences equal; no calf swelling or tenderness |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Invasive ductal carcinoma of the right male breast, central (retroareolar) portion, stage IIA (pT1c pN1a M0), grade 2, ER positive, PR positive, HER2 negative; treated by bilateral mastectomy and right axillary lymph node dissection; on adjuvant tamoxifen; synthetic modern detail linked to his publicly disclosed breast cancer | active | confirmed | C50.121 | S — Synthetic tumor size, grade, receptor status, and stage; the diagnosis, the right side, the operation, and the spread to lymph nodes are from his public account (D). |
| Estrogen receptor-positive status of the breast cancer | active | confirmed | Z17.0 | S — Synthetic receptor result; his tumor biology was not made public. |
| Long-term use of tamoxifen, with safety monitoring (venous thromboembolism, mood, hot flashes, sexual side effects, adherence) and bone health review | active | confirmed | Z79.810 | S — Synthetic adjuvant therapy in the modern episode. |
| Absence of both breasts after bilateral mastectomy | active | confirmed | Z90.13 | S — The double mastectomy is reported publicly (D); the coding is synthetic. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Cancer-related history and examination of both sides of the chest wall and both axillae | Every 3 to 6 months for 3 years | Completed today | No evidence of recurrence |
| Examination | Lymphedema assessment | Every visit after axillary surgery | Completed today | No arm swelling |
| Medication safety | Venous thromboembolism symptoms on tamoxifen | Every visit on tamoxifen | Completed today | None |
| Medication safety | Hot flashes on tamoxifen | Every visit on tamoxifen | Completed today | Mild and stable |
| Medication safety | Sexual side effects of tamoxifen (libido, erectile function) | Every visit on tamoxifen | Completed today | Lower libido; erections adequate; no treatment wanted |
| Medication safety | Sexual side effects missed at the last visit | Every visit on tamoxifen | Deferred | Not asked at the previous visit, a deviation from the protocol. Asked today: a mild fall in libido that he had not raised himself and that has not affected his adherence, so no harm resulted. The question is now on his visit checklist, because men often do not mention these effects unless asked |
| Medication safety | Adherence to tamoxifen | Every visit on tamoxifen | Completed today | No missed doses by pill organizer |
| Survey | Distress and depression screen (PHQ-2) | Every visit | Completed today | PHQ-2 score 1 |
| Laboratory | 25-hydroxyvitamin D | Three months after starting a supplement | Completed today | 36 ng/mL, up from 24 |
| Laboratory | Germline multigene panel testing | Once, for every man with breast cancer | Up to date | No pathogenic variant; result reviewed with the genetic counselor four weeks ago |
| Self-management | Genetic counseling and information for relatives | With the germline result | Completed today | Family letter given; no relative is named in the record |
| Imaging | Breast imaging (mammography) | Yearly only for a remaining breast after lumpectomy, or the other breast with a predisposing variant | Not indicated | Both breasts were removed; there is no breast tissue to image |
| Laboratory | Routine blood tests, tumor markers, and CT, bone scan, or PET | Not recommended without symptoms in stage I to III disease | Not indicated | No symptoms suggesting recurrence |
Goal progress:
Guideline basis: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); Bedrosian I, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024;42(5):584-604 (2024); Shapiro CL, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026)
Follow-up: Survivorship visit in three months. Medical oncology review as scheduled. Next scheduled visit 2003-08-11: survivorship visit: cancer-related history and examination, tamoxifen review, and written survivorship care plan. [S]